ReviewCellular and molecular life sciences : CMLS2012
Decoding the non-coding RNAs in Alzheimer's disease.
Review in Cellular and molecular life sciences : CMLS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review.Metabolic brain disease · 2024Pooled it
- PRIP: A Protein-RNA Interface Predictor Based on Semantics of Sequences.Life (Basel, Switzerland) · 2022Article
- LncRNA SNHG1 promotes neuronal injury in Parkinson's disease cell model by miR-181a-5p/CXCL12 axis.Journal of molecular histology · 2021Article
- The Regulation of microRNAs in Alzheimer's Disease.Frontiers in neurology · 2020Review
- Cerebral Amyloid Angiopathy, Alzheimer's Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets.Neuromolecular medicine · 2019Review
- LncRNA MALAT1 gene polymorphisms in coronary artery disease: a case-control study in a Chinese population.Bioscience reports · 2019Article
- Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders.Frontiers in aging neuroscience · 2019Review
- MicroRNA-181c Ameliorates Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats.Molecular neurobiology · 2017Article
- Article
- CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.Molecular neurobiology · 2017Article
- Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease.Nutrients · 2017Review
- Long non-coding RNAs and complex diseases: from experimental results to computational models.Briefings in bioinformatics · 2017Review
- Altered Long Noncoding RNA Expression Precedes the Course of Parkinson's Disease-a Preliminary Report.Molecular neurobiology · 2017Article
- A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease.Biochemical and biophysical research communications · 2017Review
- Long noncoding RNAs: Central to nervous system development.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2016Review
- Systematic Analysis of Long Noncoding RNAs in the Senescence-accelerated Mouse Prone 8 Brain Using RNA Sequencing.Molecular therapy. Nucleic acids · 2016Article
- Diagnostic Value of microRNA for Alzheimer's Disease: A Systematic Review and Meta-Analysis.Frontiers in aging neuroscience · 2016Review
- miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2016Review
- MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9.Biochimica et biophysica acta · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-coding RNAs (ncRNAs) are integral components of biological networks with fundamental roles in regulating gene expression. They can integrate sequence information from the DNA code, epigenetic regulation and functions of multimeric protein complexes to potentially determine the epigenetic status and transcriptional network in any given cell. Humans potentially contain more ncRNAs than any other species, especially in the brain, where they may well play a significant role in human development and cognitive ability. This review discusses their emerging role in Alzheimer's disease (AD), a human pathological condition characterized by the progressive impairment of cognitive functions. We discuss the complexity of the ncRNA world and how this is reflected in the regulation of the amyloid precursor protein and Tau, two proteins with central functions in AD. By understanding this intricate regulatory network, there is hope for a better understanding of disease mechanisms and ultimately developing diagnostic and therapeutic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.